Managers

October IPO Profiles: Allogene, biotech continue to lead the way

Monthly recap of fund briefs through Nov. 15

Wonder Ventures collects $15 mln for sophomore fund

Wonder Ventures has raised $15 million for its second fund, according to a blog post. Wonder Ventures II is seeking to invest in Los Angeles-based tech startups. The fund's limited partners include institutional fund-of-funds and large family offices.

Sift Healthcare inks $1 mln

Milwaukee-based Sift Healthcare, a revenue cycle intelligence company, has secured $1 million in funding. The investors included Winnebago Seed Fund and Wind River Financial.

Cannatech: Cultivating marijuana’s green valleys

VCs on the Move, monthly recap as of Nov. 15

Q&A with Boris Wertz, founding partner of Version One Ventures

Version One Ventures is growing its franchise. The Vancouver firm, founded in 2012 by renowned seed investor Boris Wertz, made the decision to expand when raising its third fund. One result was the September promotion of Angela Tran Kingyens to general partner. A further step will soon be taken with the hire of an associate. In an interview with PE Hub Canada , Wertz said the increased resources will help deploy Version One Ventures III, which raised about $57 million last month. He also told us more about Version One's growing franchise, Fund III, recent deals and the firm’s evolving strategy.

RET Ventures wraps up fund at $108 mln

Real Estate Technology Ventures has closed its inaugural fund at $108 million. Real Estate Technology Ventures I will focus on real estate technology companies. The fund's limited partners include real estate investment trusts, Aimco, Boardwalk, Essex, MidAmerica, UDR, Starwood Capital Group, Cortland and GID.

Renalytix AI lands $29 mln

UK-based Renalytix AI plc, a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, has secured $29 million in funding. The investors were not named.

Cadent Therapeutics rakes in $40 mln Series B

Cadent Therapeutics, a developer of therapies focused on movement and cognitive disorders, has raised $40 million in Series B financing. Cowen Healthcare Investments and Atlas Venture led the round with participation from Qiming Venture Partners, Access Industries, Clal Biotechnology Industries and Novartis Institutes for Biomedical Research. In addition, the company has appointed Dr. Bob Dagher as chief medical officer.